These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 17229191

  • 1. Fluvastatin and cancer.
    Mascitelli L, Pezzetta F.
    Int J Clin Pract; 2007 Jan; 61(1):168; author reply 168-9. PubMed ID: 17229191
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
    Jacobson TA, Amorosa LF.
    Am J Cardiol; 1994 May 26; 73(14):25D-29D. PubMed ID: 8198020
    [Abstract] [Full Text] [Related]

  • 9. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J, Yamamoto K, Kobori S, Setoguchi Y, Sato Y, Matsunaga A, Shichiri M, Sakai T, Kono S, Arakawa K.
    Int J Clin Pharmacol Ther; 1995 Jul 26; 33(7):420-6. PubMed ID: 7582401
    [Abstract] [Full Text] [Related]

  • 10. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
    Greten H, Beil FU, Schneider J, Weisweiler P, Armstrong VW, Keller C, Klör HU, von Hodenberg E, Weidinger G, Eskötter H.
    Am J Med; 1994 Jun 06; 96(6A):55S-63S. PubMed ID: 8017468
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
    Sasaki S, Nakagawa M, Nakata T, Endo N, Miyao K, Kitamura K, Fukuyama M, Kitani T, Yamada C.
    Cardiology; 1997 Jun 06; 88(2):160-5. PubMed ID: 9096917
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Updated clinical safety experience with fluvastatin.
    Jokubaitis LA.
    Am J Cardiol; 1994 May 26; 73(14):18D-24D. PubMed ID: 8198019
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fluvastatin, rhabdomyolysis, and myotoxicity.
    Murinson BB, Maragakis NJ, Jacobson TA.
    Mayo Clin Proc; 2008 Nov 26; 83(11):1296; author reply 1297. PubMed ID: 18990330
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The use of fluvastatin in cardiovascular risk management.
    McDonald KJ, Jardine AG.
    Expert Opin Pharmacother; 2008 Jun 26; 9(8):1407-14. PubMed ID: 18473714
    [Abstract] [Full Text] [Related]

  • 20. Fluvastatin versus pravastatin.
    Chilton R.
    Am J Cardiol; 1996 Jul 01; 78(1):127. PubMed ID: 8712106
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.